First immunogenicity data for the UK serogroup B meningococcal vaccination schedule in infants.
作者信息
McNamara Lucy A, Mbaeyi Sarah
机构信息
Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Office of the Director, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
出版信息
Lancet Infect Dis. 2021 May;21(5):586-587. doi: 10.1016/S1473-3099(20)30690-3. Epub 2021 Jan 8.
Abstract
摘要
相似文献
1
First immunogenicity data for the UK serogroup B meningococcal vaccination schedule in infants.英国婴儿B群脑膜炎球菌疫苗接种计划的首批免疫原性数据。
Lancet Infect Dis. 2021 May;21(5):586-587. doi: 10.1016/S1473-3099(20)30690-3. Epub 2021 Jan 8.
2
Meningococcal disease: Can we predict the unpredictable?脑膜炎球菌病：我们能否预测不可预测之事？
Med Clin (Barc). 2020 Jan 10;154(1):20-22. doi: 10.1016/j.medcli.2019.04.035. Epub 2019 Jul 23.
3
Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study.在台湾，将脑膜炎 B 型重组疫苗与常规疫苗一起接种给健康婴儿的安全性和免疫原性：一项 3 期、开放性、随机研究。
Hum Vaccin Immunother. 2018 May 4;14(5):1075-1083. doi: 10.1080/21645515.2018.1425659. Epub 2018 Feb 15.
4
Meningococcal group B vaccines.脑膜炎 B 型球菌疫苗。
Hum Vaccin Immunother. 2013 Jun;9(6):1387-8. doi: 10.4161/hv.24689. Epub 2013 Jun 6.
5
Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.根据不同的免疫接种计划评估婴儿接种多组份脑膜炎球菌 B 型疫苗（4CMenB）的菌株覆盖率。
Hum Vaccin Immunother. 2019;15(3):725-731. doi: 10.1080/21645515.2018.1537756. Epub 2019 Jan 2.
6
Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.B型脑膜炎球菌疫苗：新药。唯一针对某些B群脑膜炎球菌的疫苗。
Prescrire Int. 2008 Jun;17(95):95-7.
7
A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.脑膜炎 B 型球菌疫苗（MenB-FHbp）免疫原性、安全性及当前推荐意见的综述
J Clin Pharm Ther. 2020 Apr;45(2):270-281. doi: 10.1111/jcpt.13083. Epub 2019 Dec 9.
8
Meningococcal B immunisation in New Zealand: why haven't we seen the data?新西兰的B型脑膜炎球菌疫苗接种：为何我们还未看到相关数据？
N Z Med J. 2008 Mar 14;121(1270):107-9.
9
4CMenB journey to the 10-year anniversary and beyond.4CMenB 的十年历程及未来展望。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2357924. doi: 10.1080/21645515.2024.2357924. Epub 2024 Jul 8.
10
The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public health.脑膜炎 B 型（MenB）疫苗（Bexsero®）引入国家婴儿免疫计划——公共卫生的新挑战。
J Infect. 2015 Dec;71(6):611-4. doi: 10.1016/j.jinf.2015.09.035. Epub 2015 Oct 2.
引用本文的文献
1
Vaccination coverage among school children in Western Greece from 2016 to 2019.2016 年至 2019 年希腊西部学龄儿童的疫苗接种覆盖率。
Hum Vaccin Immunother. 2021 Nov 2;17(11):4535-4541. doi: 10.1080/21645515.2021.1967040. Epub 2021 Sep 2.
本文引用的文献
1
Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England.英格兰婴儿接种脑膜炎 B 型疫苗（4CMenB）。
N Engl J Med. 2020 Jan 23;382(4):309-317. doi: 10.1056/NEJMoa1901229.
2
Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.根据不同的免疫接种计划评估婴儿接种多组份脑膜炎球菌 B 型疫苗（4CMenB）的菌株覆盖率。
Hum Vaccin Immunother. 2019;15(3):725-731. doi: 10.1080/21645515.2018.1537756. Epub 2019 Jan 2.
3
Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial.婴儿4CMenB疫苗减量接种程序及儿童补种程序：一项随机开放标签3b期试验的免疫原性和安全性结果
Vaccine. 2017 Jun 16;35(28):3548-3557. doi: 10.1016/j.vaccine.2017.05.023. Epub 2017 May 19.
4
Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment.2007-08 年和 2014-15 年期间，英格兰、威尔士和北爱尔兰的多组份 4CMenB 疫苗对脑膜炎奈瑟菌 B 群菌株的覆盖率及其相应的地域分布和临床特征：定性和定量评估。
Lancet Infect Dis. 2017 Jul;17(7):754-762. doi: 10.1016/S1473-3099(17)30170-6. Epub 2017 Mar 30.
5
Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England.B型脑膜炎球菌疫苗对英格兰地方性高毒力脑膜炎奈瑟菌W菌株的有效性
Emerg Infect Dis. 2016 Feb;22(2):309-11. doi: 10.3201/eid2202.150369.
6
Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?多组份脑膜炎奈瑟菌 B 型疫苗（4CMenB）能否控制非洲脑膜炎奈瑟菌 X 群暴发？
Vaccine. 2013 Feb 4;31(7):1113-6. doi: 10.1016/j.vaccine.2012.12.022. Epub 2012 Dec 20.
Zotero 插件